Adenomyosis Market

Market Overview:

The 7 major adenomyosis markets reached a value of USD 218.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 364.5 Million by 2035, exhibiting a growth rate (CAGR) of 4.81% during 2025-2035.

The adenomyosis market has been comprehensively analyzed in IMARC's new report titled "Adenomyosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Adenomyosis is a condition that occurs when endometrial tissue begins to develop into the muscular wall of the uterus. It causes the uterus to thicken and enlarge—sometimes up to twice or triple its normal size. Adenomyosis can cause painful periods, heavy or extended menstrual flow that clots, and abdominal/pelvic pain. In many cases, there are no indications. When symptoms appear, they may include pain during or after sexual activity, infertility, enlarged uterus, bloating or fullness in the belly, bleeding between periods, fatigue, anemia, pressure on the bladder or rectum, etc. Diagnosing this ailment commonly involves a comprehensive clinical evaluation, medical history, and physical examination. The healthcare provider may also utilize imaging tests, such as transvaginal ultrasound and magnetic resonance imaging, to visualize the uterine wall and confirm the diagnosis. Furthermore, an endometrial biopsy might be performed, which involves taking a small tissue sample from the lining of the uterus (endometrium) and examining it under a microscope.

The escalating prevalence of inflammation of the uterine lining during or after childbirth that could potentially disrupt the boundary between the endometrium and myometrium, is primarily driving the adenomyosis market. In addition to this, the inflating utilization of non-steroidal anti-inflammatory drugs (NSAIDs), like ibuprofen and naproxen to help alleviate menstrual cramps and pain, is also creating a positive outlook for the market. Moreover, the widespread adoption of levonorgestrel-releasing intrauterine system, since it works for adenomyosis by locally releasing progestin (levonorgestrel) to reduce endometrial blood flow, decrease the number of estrogen receptors, and improve symptoms is further bolstering the market growth. Apart from this, the rising usage of hysterectomy that can offer complete relief from indications, like heavy bleeding and pain, thereby significantly improving quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of high-intensity focused ultrasound, which uses focused ultrasound energy to destroy the affected tissue, offering a uterus-sparing approach with potential benefits for fertility, is expected to drive the adenomyosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the adenomyosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adenomyosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adenomyosis market in any manner.

Drugs:

Dienogest acts as a progestin, which means it attaches to progesterone receptors in the uterus and mimics the effects of progesterone. It causes a reduction in endometrial thickness and activity by attaching to progesterone receptors. The medicine also inhibits the pituitary gland's secretion of gonadotropins (FSH and LH), limiting ovarian estrogen production. By suppressing estrogen, dienogest reduces the growth and proliferation of endometrial tissue, both in the uterus and in any ectopic locations, and inhibits the formation of new blood vessels (angiogenesis) in the endometrium.

Linzagolix choline, developed by Kissei Pharmaceutical/ObsEva, is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adenomyosis. It reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to suppressed estrogen production. This lowers endometrial inflammation, pain, and abnormal bleeding associated with adenomyosis. The drug allows for dose-dependent estrogen suppression, balancing symptom relief while minimizing bone density loss and menopausal side effects.

Quinagolide is a dopamine D2 receptor agonist used for adenomyosis. It inhibits prolactin secretion, which may help regulate estrogen-driven endometrial growth and reduce inflammation and vascularization in adenomyotic lesions. By modulating dopaminergic pathways, Quinagolide potentially alleviates pain, abnormal bleeding, and lesion progression, offering a non-hormonal therapeutic option for managing adenomyosis symptoms while minimizing systemic estrogen suppression.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the adenomyosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the adenomyosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current adenomyosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the adenomyosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the adenomyosis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the adenomyosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of adenomyosis across the seven major markets?
• What is the number of prevalent cases (2019-2035) of adenomyosis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of adenomyosis by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with adenomyosis across the seven major markets?
• What is the size of the adenomyosis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of adenomyosis?
• What will be the growth rate of patients across the seven major markets?

Adenomyosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for adenomyosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adenomyosis market?
• What are the key regulatory events related to the adenomyosis market?
• What is the structure of clinical trial landscape by status related to the adenomyosis market?
• What is the structure of clinical trial landscape by phase related to the adenomyosis market?
• What is the structure of clinical trial landscape by route of administration related to the adenomyosis market?